My PD Story

Zoltan Arany headshot.
Researchers

Zoltan Arany, MD, PhD

2026 Impact Award

How Turning Off a Cell Recycling Suppressor Could Strengthen Neurons Against Parkinson’s

In Parkinson’s disease (PD), fragile neurons in the brain break down over time. Commonly, the reason these neurons break down is because they accumulate clumps of a misshapen protein called alpha-synuclein. These clumps clog the neuron, disrupting critical parts of the cell and eventually causing enough dysfunction that the neuron dies.

Autophagy is the process cells use to dissolve and recycle junk like alpha-synuclein clumps. However, autophagy regulation is often disrupted in PD, preventing neurons from effectively cleaning up their alpha-synuclein messes. Stimulating this recycling process could be an important therapy for PD, helping to clear alpha-synuclein buildup in cells. 

Zoltan Arany, MD, PhD, recipient of a Parkinson’s Foundation Impact Award, believes that by turning off a cellular switch called FLCN, we can reactivate autophagy in PD-affected neurons and help prevent their degeneration.

“If successful, this research would show that FLCN is a promising treatment target of PD and lead to new therapies.” – Dr. Arany

One important regulator of autophagy in cells is a group of proteins called mTORC1, which slows down the recycling processes. Scientists initially thought that turning mTORC1 off completely in PD neurons would jumpstart autophagy and help clean up the alpha-synuclein clumps. Unfortunately, doing so caused wider damage instead, since mTORC1 is involved in other important cell processes as well. These results indicated that a more targeted regulator of mTORC1 needed to be found. 

Zoltan Arany uses a pipette to transfer liquid into a petri dish in a laboratory.

Dr. Arany and his colleagues at the University of Pennsylvania, a Parkinson’s Foundation Center of Excellence, recently discovered that mTORC1 is supported by another protein called FLCN. FLCN works by regulating very specific components of mTORC1. When they turned off FLCN in liver cells, they found that autophagy was improved without causing the widespread disruption seen when mTORC1 itself was turned off.

Now, Dr. Arany will see if turning off FLCN in neurons has similar results. They will use both neurons grown in petri dishes (in vitro) as well mice (in vivo) to test if halting FLCN could have positive effects on autophagy. After that, they will see how the anti-FLCN treatment affects neurons with alpha-synuclein clumps in them, simulating PD conditions.

If turning off FLCN in neurons helps them manage alpha-synuclein clumping, this work could kickstart the development of future FLCN-focused therapies for people with PD. 

“My father had PD. He was an amazing, warm, kind, generous and brilliant man,” said Dr. Arany. “The idea that I could make a difference in the lives of other people with PD is tremendously meaningful to me.”

Meet more Parkinson’s researchers! Explore our My PD Stories featuring PD researchers.

Back to Top